ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
Different dosing enlivens Enliven’s share price
ELVN-001 is made to look more like Terns’ TERN-701.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
The month ahead: January’s remaining events
JP Morgan approaches.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
